uploads///Aranesp

How Amgen’s Aranesp, Epogen and Sensipar Did in 1Q18

By

May. 8 2018, Updated 8:00 a.m. ET

Aranesp revenue trends

In 1Q18, Amgen’s (AMGN) Aranesp revenue fall 11% YoY (year-over-year) to $454 million from $511 million, primarily due to lower unit demand and increased competition. It fell ~8% QoQ (quarter-over-quarter).

In US and international markets, Aranesp generated revenue of $225 million and $229 million, respectively, compared with $278 million and $233 million in 1Q17. Aranesp, an erythropoietin-stimulating agent, competes with Johnson & Johnson’s (JNJ) Eprex and Pfizer’s (PFE) Retacrit.

Article continues below advertisement

Epogen revenue trends

In 1Q18, Epogen revenue fell 10% YoY and QoQ to $244 million from $270 million, primarily due to lower net selling prices due to Amgen’s extended supply agreement with DaVita and lower unit demand. Amgen’s Epogen competes with Johnson & Johnson’s (JNJ) Procrit.

Sensipar revenue trends

In 1Q18, Amgen’s Sensipar revenue grew 18% YoY to $497 million from $421 million, primarily due to higher unit demand. It grew 20% QoQ.

In US and international markets, Sensipar generated revenue of $409 million and $88 million, respectively, compared with $337 million and $84 million in 1Q17. Sensipar is used to treat adults with secondary hyperparathyroidism and chronic kidney disease.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.